Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Sci Signal. Author manuscript; available in PMC 2010 May 10.
Published in final edited form as:
Sci Signal. 2010 January 12; 3(104): ra2.
doi: 10.1126/scisignal.2000526

Fig. 4

An external file that holds a picture, illustration, etc.
Object name is nihms-189253-f0004.jpg

Validation of O-GlcNAcylation site mapping. (A, C, and E)FETDMS/MS spectra recorded on (A) [M + 4H]+4 ions (m/z 815.6) for the modified peptide, gSTEANVLPPSgSIGFTFSVPVAK, from NUP153; (C) [M + 3H]+3 ions (m/z 531.9) for the modified peptide, TITVPVgSGSPK, from EMSY; (E) [M + 3H]+3 ions (m/z 499.2) for the modified peptide, SAPAgSQASLR, from NUMA. Abbreviations for the amino acid residues are as follows: A, Ala; E, Glu; F, Phe; G, Gly; I, Ile; K, Lys; L, Leu; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; and V, Val. Predicted m/z values for product ions of type c′ and type z′•(monoisotopic and average masses for singly and doubly charged ions, respectively) are listed above and below the peptide sequence. Observed product ions are underlined and also labeled in the spectrum. Ions in the precursor isolation window are labeled with a triangle ([triangle]). Brackets enclose ions corresponding to charge-reduced species, as well as fragments derived from these charge-reduced species. Product ions resulting from loss of an aminomethyl triazole radical are labeled with a circle (●). Insert displays the isotopic distribution, calculated monoisotopic mass, and experimental monoisotopic mass of precursor ions corresponding to the labeled and unlabeled forms of the indicated peptide. (B, D, and F) Nup153, NuMA1, or EMSY were immunopurified from lysates of thymidine-nocodazole synchronized cells overexpressing either GFP or OGT. Precipitates were washed, separated on SDS-PAGE, and transferred to membranes for blotting. Membranes were probed for O-GlcNAc. For Nup153 and NuMA1, the increase in O-GlcNAc in the samples from the OGT-overexpressing cells is evident. For EMSY, the increase is not readily apparent, which may be due to only one of seven O-GlcNAcylation sites exhibiting increased modification.

Images in this article

  • Fig. 1
  • Fig. 2
  • Fig. 3
  • Fig. 4
  • Fig. 5
  • Fig. 6
  • Fig. 7
Click on the image to see a larger version.